St. Louis Park, Minnesota Clinical Trials

A listing of St. Louis Park, Minnesota clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 450 clinical trials
Featured trial
Nuestros Días: Study on the Daily Experiences of Latino/a Family Caregivers

By taking part in this study, participants will help us understand how stressful events impact their well-being as caregivers/care partners of a relative living with memory problems or dementia. Participants will help us identify factors that increase resilience to stress and help us establish the evidence base for culturally responsive, …

Online studies
Accepts healthy volunteers
Online Study Center
(online study) Contact site
  • 21 views
  • 30 May, 2023
  • 1 location
  • Online study
Featured trial
Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis

www.MyelofibrosisResearch.com Myelofibrosis is a type of bone marrow cancer that usually develops slowly and disrupts body's normal production of blood cells. It causes bone marrow scarring, leading to severe anemia that can cause weakness and fatigue. It can also cause a low number of blood-clotting cells called platelets, which increases …

Minnesota Oncology Hematology, /ID# 227357
 (6.3 away) Contact site
  • 380 views
  • 23 Oct, 2022
  • +149 other locations
Featured trial
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) (POD1UM-204)

This is a multicenter, open-label, nonrandomized, Phase 2 umbrella study of retifanlimab in participants who have advanced or metastatic endometrial cancer that has progressed on or after platinum-based chemotherapy. retifanlimab will be administered as monotherapy or in combination with other immunotherapy or targeted agents.

metastatic endometrial cancer
cancer
platinum-based chemotherapy
Minnesota Oncology - Maplewood
 (5.3 away) Contact site
  • 59 views
  • 25 Oct, 2022
  • +52 other locations
Featured trial
PROSEEK: A Phase 2 Study In Early Parkinson's Disease Patients Evaluating The Safety And Efficacy Of Abl Tyrosine Kinase Inhibition Using K0706

This study consists of 2 parts. Part 1 of the study is conducted to evaluate the efficacy, safety, and tolerability of two doses of K0706 compared to placebo in subjects with early Parkinson's Disease who are not receiving dopaminergic therapy. Part 2 is an optional long term extension study for …

early parkinson's
Struthers Parkinson's Center -Park Nicollet
 (3.9 away) Contact site
  • 105 views
  • 02 Jun, 2023
  • +76 other locations
Featured trial
A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Leukemia

This is a nonrandomized study of ruxolitinib in combination with a standard multi-agent chemotherapy regimen for the treatment of B-cell acute lymphoblastic leukemia. Part 1 of the study will optimize the dose of study drug (ruxolitinib) in combination with the chemotherapy regimen. Part 2 will evaluate the efficacy of combination …

cytarabine
dexamethasone
cyclophosphamide
asparaginase
combination chemotherapy
Children'S Hlth Care Mnpls
 (5.3 away) Contact site
  • 5 views
  • 28 Oct, 2022
  • +93 other locations
A Phase III Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Ocrelizumab In Adult Patients With Primary Progressive Multiple Sclerosis. (FENtrepid)

A study to evaluate the efficacy and safety of fenebrutinib on disability progression in adult participants with Primary Progressive Multiple Sclerosis (PPMS). All eligible participants will be randomized 1:1 to either daily oral fenebrutinib (or placebo) or intravenous (IV) ocrelizumab (or placebo) in a blinded fashion through an interactive voice …

Minneapolis Clinic of Neurology
 (3.7 away) Contact site
  • 0 views
  • 18 Oct, 2022
  • +144 other locations
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecerfont (NBI-74788) in Adult Subjects With Classic Congenital Adrenal Hyperplasia, Followed by Open-Label Treatment (CAHtalyst)

This is a Phase 3 study to evaluate the efficacy, safety, and tolerability of crinecerfont versus placebo administered for 24 weeks in approximately 165 adult subjects with classic CAH due to 21-hydroxylase deficiency. The study consists of a 6 month randomized, double blind, placebo-controlled period, followed by 1 year of …

21-ohd
deficiency
Neurocrine Clinical Site
 (6.2 away) Contact site
  • 123 views
  • 18 Oct, 2022
  • +59 other locations
Gastroschisis Outcomes of Delivery (GOOD) Study

The objective of this study is to investigate the hypothesis that delivery at 35 0/7- 35 6/7 weeks in stable patients with gastroschisis is superior to observation and expectant management with a goal of delivery at 38 0/7 - 38 6/7 weeks. To test this hypothesis, we will complete a …

Children's MN, Midwest Fetal Care Center
 (5.3 away) Contact site
  • 408 views
  • 21 Oct, 2022
  • +21 other locations
Emergency Department-Initiated Buprenorphine Validation Network Trial

This study will (1) recruit, train and provide resources to approximately 30 Emergency Department (ED) sites throughout the U.S. using implementation facilitation strategies to provide ED-initiated buprenorphine (BUP) for patients presenting with opioid use disorder (OUD) who are not receiving medications for opioid use disorder (MOUD). Once implementation is adequately …

Hennepin County Medical Center
 (5.6 away) Contact site
  • 711 views
  • 22 Oct, 2022
  • +16 other locations
Lead EvaluAtion for Defibrillation and Reliability (LEADR)

The study is designed to assess the safety and efficacy of the Next Generation ICD lead.

Minneapolis Heart Institute Foundation
 (5.9 away) Contact site
  • 7 views
  • 23 Oct, 2022
  • +46 other locations